CLYM (Climb Bio) Book Value per Share : $3.15 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Climb Bio Book Value per Share?

Climb Bio's book value per share for the quarter that ended in Dec. 2024 was $3.15.

During the past 12 months, Climb Bio's average Book Value Per Share Growth Rate was -18.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Climb Bio was -20.90% per year. The lowest was -20.90% per year. And the median was -20.90% per year.

Climb Bio's current price is $1.27. Its book value per share for the quarter that ended in Dec. 2024 was $3.15. Hence, today's PB Ratio of Climb Bio is 0.40.

During the past 6 years, the highest P/B Ratio of Climb Bio was 0.40. The lowest was 0.00. And the median was 0.00.

Climb Bio Book Value per Share Historical Data

The historical data trend for Climb Bio's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Climb Bio Book Value per Share Chart

Climb Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Book Value per Share

Get a 7-Day Free Trial

-2.14

6.37

4.85

3.89

3.15

Climb Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Book Value per Share	Get a 7-Day Free Trial															3.89	3.84	3.33	3.25	3.15

Competitive Comparison of Climb Bio's Book Value per Share

For the Biotechnology subindustry, Climb Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Climb Bio's PB Ratio falls into.

Save Embed

;

Save Embed

;

Climb Bio Book Value per Share Calculation

Climb Bio's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(211.88	-	0.00)	/	67.26
	=	3.15

Climb Bio's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(211.88	-	0.00)	/	67.26
	=	3.15

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Climb Bio (NAS:CLYM) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Climb Bio Book Value per Share Related Terms

Thank you for viewing the detailed overview of Climb Bio's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Climb Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Climb Bio Inc (NAS:CLYM) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481

Website

https://www.climbbio.com

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Executives

Emily Pimblett	officer: Chief Accounting Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Valerie Morisset	officer: Chief Scientific Officer	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ai Eti Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Andrew David Levin	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg	director	C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher	officer: EVP and General Counsel	11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle	officer: COO & CFO	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik	other: Affiliate of 10% Owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe	director	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby	director, officer: Chief Executive Officer	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109